Bayer AG

Read how Bayer’s $7.25 billion Roundup settlement and U.S. special status shift investor sentiment, legal risk, and future product pricing.

Discover how Bayer’s multi‑billion‑dollar Roundup settlement reshapes its legal risk, finances, and pharma‑agri strategy—and what it means for investors.

Discover how Bayer’s new anticoagulant Asundexian could cut stroke rates, improve patient adherence, and reshape its portfolio in the competitive NOAC market.

Explore Bayer’s 2026 market outlook: modest price dip, R&D focus on kinase inhibitors, IL‑23 therapy, and CRISPR crop tech, plus investor signals for future gains.

Discover how Bayer AG’s stock surge is driven by a potential glyphosate ruling, patent cliffs, and strategic moves in pharma, biotech, and diagnostics.

Discover how Bayer AG’s new oncology, renal therapies and cardiac‑amyloidosis imaging boost growth while navigating patent loss and glyphosate litigation risks.

Explore Bayer AG’s recent share dip, valuation pressures, and how they could affect R&D, safety monitoring, and future therapeutic breakthroughs.

Explore how Bayer AG’s legal battles, Baya Solara strawberry breakthrough and cell‑specific siRNA heart therapy shape its future in pharma, agriculture, and IP strategy.

Explore Bayer AG’s 2025 surge, Cytokinetics partnership, glyphosate litigation and Monsanto integration – what fuels 2026 growth?

Explore Bayer AG’s latest share‑price rally: how Finerenon, patent expirations, and Roundup litigation shape the company’s risk‑adjusted upside.